title: Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer.
abstract: We report a case of long-term (9 years) response to 4th-line endocrine treatment with fulvestrant given for advanced breast cancer after no or poor response to prior endocrine therapies. Complete remission was achieved with full dose and maintained even after dose reduction due to unanticipated intensity of mucosal toxicity. Complete remission was temporarily lost after fulvestrant was tentatively withdrawn (63 months after treatment start), but was re-achieved after renewal of half-dose treatment and last reconfirmed 90 months after treatment start. The pharmacokinetic profile provides evidence to hypothesize a unique sensitivity to fulvestrant in this patient which might explain both: toxicity and extraordinary efficacy.
authors.affiliation: Department of Medical Oncology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
authors.forename: H
authors.initials: H
authors.lastname: Hawle
authors.forename: D
authors.initials: D
authors.lastname: Hess
authors.forename: A
authors.initials: A
authors.lastname: Mueller
authors.forename: B
authors.initials: B
authors.lastname: Thuerlimann